Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Short Interest Update

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 447,500 shares, an increase of 107.2% from the August 31st total of 216,000 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 4,475.0 days. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 4,475.0 days.

Swedish Orphan Biovitrum Price Performance

Shares of OTCMKTS BIOVF opened at $30.05 on Monday. The stock has a market cap of $10.70 billion, a PE ratio of 25.25 and a beta of 0.49. The company has a quick ratio of 0.66, a current ratio of 1.00 and a debt-to-equity ratio of 0.22. Swedish Orphan Biovitrum has a 52-week low of $25.80 and a 52-week high of $32.01. The business has a 50-day moving average price of $29.77 and a 200 day moving average price of $29.49.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.06. Swedish Orphan Biovitrum had a return on equity of 11.67% and a net margin of 16.05%.The company had revenue of $649.61 million during the quarter, compared to analysts’ expectations of $644.68 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.